KEYNOTE-716: Adjuvant pembrolizumab prolongs recurrence-free survival in resected stage II melanoma

Cabozantinib in combination with atezolizumab in patients with mCRPC

OncoAlert and ecancer - ESMO 2021 Day 2

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa

ESMO President: What to watch for at ESMO 2021

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients

Vaccinations in myeloma patients including for COVID-19

OncoAlert and ecancer weekly round up for August 16th - August 22nd, 2021

OncoAlert and ecancer weekly round up for August 2 - August 14, 2021

Myelodysplastic syndromes (MDS)